Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
12.70
+0.53 (4.35%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Korro Bio Employees
Korro Bio had 58 employees as of December 31, 2025. The number of employees decreased by 46 or -44.23% compared to the previous year.
Employees
58
Change (1Y)
-46
Growth (1Y)
-44.23%
Revenue / Employee
$78,408
Profits / Employee
-$2,316,286
Market Cap
183.17M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58 | -46 | -44.23% |
| Dec 31, 2024 | 104 | 2 | 1.96% |
| Dec 31, 2023 | 102 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| LENZ Therapeutics | 152 |
| MediWound | 121 |
| Precision BioSciences | 66 |
| Pyxis Oncology | 56 |
| OnKure Therapeutics | 45 |
| NovaBridge Biosciences | 30 |
| Unicycive Therapeutics | 22 |
KRRO News
- 4 weeks ago - Korro Bio initiated with an Outperform at LifeSci Capital - TheFly
- 4 weeks ago - Korro to Present at the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Korro Bio selects KRRO-111 as development candidate - TheFly
- 5 weeks ago - Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 5 weeks ago - Korro Bio price target lowered to $15 from $20 at H.C. Wainwright - TheFly
- 5 weeks ago - Korro Bio initiated with a Buy at Citi - TheFly
- 6 weeks ago - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Korro Bio upgraded to Buy from Hold at JonesResearch - TheFly